Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study
Document Type
Article
Publication Date
1-1-2026
Abstract
Background and Aims: – Advanced histologic fibrosis is a major predictor of mortality in metabolic dysfunction–associated steatotic liver disease (MASLD). We aimed to identify advanced fibrosis clinical determinants across diverse MASLD populations and to assess the prognostic value of noninvasive markers (NITs) of fibrosis for adverse outcomes. Approach and Results: – The Global MASLD (G-MASLD) enrolled biopsy-confirmed MASLD patients with clinical, histologic, and noninvasive test (NIT) data. Factors associated with the presence of advanced histologic fibrosis (F3-F4) in MASLD and clinical outcomes were assessed. There were 17, 792 patients with MASLD. Advanced fibrosis (≥F3) was present in 35%. The prevalence of type 2 diabetes (T2D) increased stepwise with fibrosis stage, from 28% in F0 to 70% in F4 (trend p< 0.0001). Independent predictors of advanced fibrosis included older age, T2D, and obesity, although the association with obesity varied by region. Among patients with follow-up (mean 6.6 y), 6.5% died and 10.1% experienced a clinical event. Older age, male sex, T2D, and obesity were independent predictors of both mortality and clinical events (p< 0.05). Fibrosis severity, whether defined histologically or by NITs, was strongly associated with higher risks of death and liver-related outcomes (all adjusted HR>1.0, p< 0.001). Five-year mortality was 2.1% overall, rising to 8.3% in patients with cirrhosis, and exceeded 10% among those with high-risk NIT score values. Conclusions: – In this large global biopsy-based MASLD cohort, advanced fibrosis was highly prevalent and strongly linked to T2D. Both histologic fibrosis and NITs were independent predictors of mortality and clinical outcomes, underscoring the prognostic value of fibrosis assessment with NITs.
Keywords
biomarkers, chronic liver disease, diagnostic thresholds, metabolic syndrome, noncommunicable diseases, outcomes, steatohepatitis, steatotic liver disease
Publication Title
Hepatology
ISSN
0270-9139
DOI
10.1097/HEP.0000000000001617
Recommended Citation
Younossi, Zobair M.; de Avila, Leyla; Petta, Salvatore; Hagström, Hannes; Kim, Seung Up; Nakajima, Atsushi; Crespo, Javier; Castera, Laurent; Alkhouri, Naim; Zheng, Ming Hua; Treeprasertsuk, Sombat; Ananchuensook, Prooksa; Shalimar; Tsochatzis, Emmanuel; Trivikrama, Shenoy Kotacherry; Balakumaran, Leena Kondarappassery; Fan, Jian Gao; and Roberts, Stuart K., "Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study" (2026). Research Publications (2026 to 2030). 2135.
https://knova.um.edu.my/research_publications_2026_2030/2135
Publisher
Lippincott Williams and Wilkins